Roche Holding Ltd. Share Price Swiss Exchange
Equities
CH0012032048
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- CHF | - |
|
07:25am | Roche Receives Additional Prequalification Designations for HPV Test | MT |
06-25 | Halozyme Therapeutics Says Roche's OCREVUS SC With ENHANZE Gets European Commission Approval | MT |
Sales 2024 * | 60.61B 67.56B 5,350B | Sales 2025 * | 64B 71.34B 5,649B | Capitalization | 202B 225B 17,796B |
---|---|---|---|---|---|
Net income 2024 * | 13.25B 14.77B 1,170B | Net income 2025 * | 14.76B 16.45B 1,303B | EV / Sales 2024 * | 3.56 x |
Net Debt 2024 * | 14.09B 15.7B 1,244B | Net Debt 2025 * | 9B 10.03B 795B | EV / Sales 2025 * | 3.29 x |
P/E ratio 2024 * |
14.7
x | P/E ratio 2025 * |
13.3
x | Employees | - |
Yield 2024 * |
3.92% | Yield 2025 * |
4.03% | Free-Float | 88.91% |
Latest transcript on Roche Holding Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 31/12/02 | |
Severin Schwan
CHM | Chairman | 57 | 31/12/07 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 31/03/11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 02/03/15 |
Director/Board Member | 59 | - | |
Director/Board Member | 66 | 31/12/95 |
1st Jan change | Capi. | |
---|---|---|
+54.61% | 811B | |
+44.25% | 640B | |
-6.33% | 353B | |
+20.62% | 333B | |
+10.44% | 302B | |
+18.45% | 246B | |
+13.03% | 218B | |
+8.61% | 168B | |
-4.76% | 155B |